がん化学療法による悪心・嘔吐(CINV)治療薬の世界市場2017-2021...市場調査レポートについてご紹介

【英文タイトル】Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Highlights

PART 05: Disease overview
• Understanding the disease
• Pathophysiology
• Central pathway
• Peripheral pathway
• Management of disease

PART 06: Pipeline analysis

PART 07: Market landscape
• Global CINV drugs market
• Five forces analysis

PART 08: Market segmentation by therapy
• Serotonin receptor antagonists
• NK1 receptor antoagonists
• Others

PART 09: Geographical segmentation
• CINV drugs market in Americas
• CINV drugs market in EMEA
• CINV drugs market in APAC

PART 10: Market drivers
• Growing cancer population driving the market growth
• Growing preference for chemotherapy drugs in developing countries
• Approval of new drugs fuels the market growth

PART 11: Impact of drivers

PART 12: Market challenges
• Growing popularity of alternate therapies for the treatment of cancer in developed countries
• Loss of patent exclusivities increasing generic competition
• Limitations in existing therapies hindering the growth prospects

PART 13: Impact of drivers and challenges

PART 14: Market trends
• Robust R&D activities fueling the pipeline
• Increasing inorganic growth strategies likely to fuel the market growth
• Novel treatment options coupled with new applications

PART 15: Vendor landscape
• Competitive scenario

PART 16: Key vendor analysis
• GlaxoSmithKline
• Helsinn
• Heron Therapeutics
• Merck
• Tesaro
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Pipeline landscape
Exhibit 03: Key pipeline candidates
Exhibit 04: Global CINV drugs market snapshot
Exhibit 05: Analysis of global CINV drugs market
Exhibit 06: Global CINV drugs market 2016-2021 ($ billions)
Exhibit 07: Key initiatives in emerging economies
Exhibit 08: Opportunity analysis of global CINV drugs market
Exhibit 09: Opportunity analysis in developed and emerging markets
Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global CINV drugs market by therapy 2016 (% share)
Exhibit 12: Lifecycle analysis of segments in global CINV drugs market
Exhibit 13: Geographic segmentation by revenue 2016 and 2021
Exhibit 14: Geographic segmentation by revenue 2016 ($ millions)
Exhibit 15: Market scenario in Americas
Exhibit 16: CINV drugs market in Americas 2016-2021 ($ millions)
Exhibit 17: Market scenario in EMEA
Exhibit 18: CINV drugs market in EMEA 2016-2021 ($ millions)
Exhibit 19: Market scenario in APAC
Exhibit 20: CINV drugs market in APAC 2016-2021 ($ millions)
Exhibit 21: Key drivers and challenges in APAC
Exhibit 22: Top ten cancers in the US in 2013
Exhibit 23: Key approvals in the market in 2015 and 2016
Exhibit 24: Impact of drivers
Exhibit 25: Merck: YoY revenue and growth rate of EMEND 2013-2015 ($ millions)
Exhibit 26: Forcefield analysis of drivers and challenges
Exhibit 27: Impact of drivers and challenges
Exhibit 28: Key vendors that are extensively conducting R&D activities
Exhibit 29: Competitive structure analysis of global CINV drugs market 2015
Exhibit 30: Market share analysis in global CINV drugs market
Exhibit 31: Competitive analysis of global CINV drugs market
Exhibit 32: Market penetration of various global CINV drugs manufacturers 2015
Exhibit 33: GlaxoSmithKline: Strength assessment
Exhibit 34: GlaxoSmithKline: Strategy assessment
Exhibit 35: GlaxoSmithKline: Opportunity assessment
Exhibit 36: Helsinn: Key highlights
Exhibit 37: Helsinn: Strength assessment
Exhibit 38: Helsinn: Strategy assessment
Exhibit 39: Helsinn: Opportunity assessment
Exhibit 40: Heron Therapeutics: Key highlights
Exhibit 41: Heron Therapeutics: Strength assessment
Exhibit 42: Heron Therapeutics strategy assessment
Exhibit 43: Heron Therapeutics: Opportunity assessment
Exhibit 44: Merck: Key highlights
Exhibit 45: Merck: strength assessment
Exhibit 46: Merck: Strategy assessment
Exhibit 47: Merck: Opportunity assessment
Exhibit 48: Merck: YoY revenue and growth rate of EMEND 2013-2015 ($ millions)
Exhibit 49: Tesaro: Key highlights
Exhibit 50: Tesaro: Strength assessment
Exhibit 51: Tesaro: Strategy assessment
Exhibit 52: Tesaro: Opportunity assessment


【レポート販売概要】

■ タイトル:がん化学療法による悪心・嘔吐(CINV)治療薬の世界市場2017-2021
■ 英文:Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021
■ 発行日:2016年12月29日
■ 調査会社:Technavio
■ 商品コード:IRTNTR11320
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。